What should you know about delytact glioblastoma?

Its generic name is teserpaturev, also called G47 delta. It is made from a modified herpes simplex virus and requires direct administration by a specialist neurosurgical team. Access, regulatory status and eligible tumour settings differ by country, so it is not a routine option in every treatment centre.

The modified virus is designed to multiply preferentially within tumour cells, causing cell damage and exposing tumour material to the immune system. This differs from chemotherapy, which travels through the body, and radiotherapy, which directs radiation at a planned area. Delytact does not replace the need to assess surgery, radiotherapy, chemotherapy and supportive care.

Suitability depends on the exact diagnosis, where the tumour is located, previous treatments, current neurological function, immune health and whether the medicine is locally authorised or available through a clinical trial. A multidisciplinary brain tumour team should weigh these factors and explain the realistic aim of treatment.

Bring the neuro-oncology team a current medicine list and details of seizures, infections, immune-suppressing conditions, steroid use and previous reactions to herpes medicines. Ask how Delytact would be delivered, whether hospital observation is expected and how the team will reduce exposure risk for household members or caregivers. Follow all wound, hygiene and contact precautions supplied by the centre.

Scheduled neurological examinations and brain imaging help the team assess recovery and tumour behaviour. Treatment-related inflammation can complicate scan interpretation, so symptoms, examination findings and changes across scans are considered together. Do not alter steroids or anti-seizure medicines unless the treating team gives instructions.

Call emergency services for a first seizure, a seizure that lasts longer than the care plan allows, loss of consciousness, severe breathing difficulty or sudden weakness on one side. Seek urgent assessment for a rapidly worsening headache, repeated vomiting, new confusion, speech difficulty, vision change or increasing drowsiness because these can signal pressure or swelling in the brain. Contact the treatment centre promptly for fever, a spreading blister-like rash, wound redness or drainage, or any new neurological symptom after administration.

Discuss whether the tumour diagnosis and location meet local eligibility criteria, what benefit the team hopes to achieve and which alternatives remain available. Ask about procedure-related risks, viral precautions, monitoring, effects on later treatment and whether participation in a clinical trial is required.